Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients

医学 玻璃微球 微球 前瞻性队列研究 队列 队列研究 选择性内照射治疗 放射治疗 放射科 外科 内科学 肝细胞癌 临床试验 内辐射 外束辐射 核医学 梅德林
作者
Boris Guiu,Clément Bailly,Éric Vibert,Ghoufrane Tlili,Denis Mariano‐Goulart,Julien Edeline,Yann Touchefeu,Emmanuel Durand,Jean Frédéric Blanc,Julia Chalaye,Hélène Regnault,Antoine Bouvier,Géraldine Sergent,Christian Sengel,Stéphane Renaud,Agnès Rode,Claude Somma,P. Chevallier,Vincent Habouzit,I. Brenot-Rossi
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:95: 103884-103884 被引量:9
标识
DOI:10.1016/j.eclinm.2026.103884
摘要

Background: Selective Internal Radiation Therapy with yttrium-90 (Y90) has been used for decades, yet guideline recommendations remain inconsistent. High-quality real-world data is needed to guide practice. The objectives of this study were to evaluate effectiveness, safety, and patient quality of life (QoL) with TheraSphere™ treatment in real-world clinical practice, and to identify clinical and dosimetric factors associated with survival. Methods: PROACTIF was a prospective, open label, non-interventional, all-comers cohort study that recruited patients who received Y90 glass microspheres (TheraSphere™) per local standard of care across 34 French sites (January 2019-January 2024). Co-primary endpoints were overall survival (OS) and QoL. Secondary endpoints included safety, conversion to surgery, and factors associated with OS. OS and time-to-deterioration in QoL (Functional Assessment of Cancer Therapy-Hepatobiliary) were assessed by Kaplan-Meier analysis. Adverse events were descriptively summarized using Common Terminology Criteria for Adverse Events, version 5. Trial registration: ClinicalTrials.gov Identifier, NCT04069468. Findings: Amongst 989 HCC patients, 13·3%/18·9%/57·9%/5·8% were Barcelona Clinic Liver Cancer (BCLC) A/B/C/D, respectively; 35·3% had portal-vein tumor thrombosis (PVT); 74·4% were treated using multicompartment dosimetry, and 53·6% with selective Y90 administration. Mean index lesion dose was 435·4 Gy. For all patients, median OS (mOS) [95% CI] was 21·8 months (M) [20·1-23·3]. mOS was 27·0 M [20·7-31·4] for BCLC B, 21·1 M [18·0-22·8] for BCLC C; 23·1 M [21·6-27·0] without PVT, 24·8 M [19·3-30·3] for patients with Vp1/Vp2; 16·8 M mOS for patients with a pretreatment absorbed dose to the index lesion <200 Gy versus 26·0 M with ≥200 Gy (p < 0·001); 19·7 M for <400 Gy and 30·7 M for ≥400 Gy (p < 0·001). After Y90, 106/989 (10·7%) underwent curative-intent surgery, resulting in a mOS of 48·6 M [40·6-not evaluable], versus 20·1 M [17·7-21·7] without surgery. Median time-to-deterioration in QoL was 10·6 M [9·6-11·7]. Serious adverse events occurred in 7·5% patients; serious treatment-related events in 3·7%. Interpretation: In this large real-world cohort, treatment with Y90 glass microspheres demonstrated favorable effectiveness and safety with meaningful outcomes, especially in PVT patients and following subsequent surgery. PROACTIF showed a strong dose-survival relationship as demonstrated in previous studies, and highlights the potential of a tumor absorbed dose ≥400 Gy to further increase survival. These findings support dosimetry-guided Y90 across all BCLC stages, and should inform future guideline recommendations. Funding: Boston Scientific Corporation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
2秒前
888发布了新的文献求助100
2秒前
2秒前
shangguang的应助被江篱采纳,获得10
2秒前
何hehe发布了新的文献求助30
2秒前
gela发布了新的文献求助10
3秒前
1793480753发布了新的文献求助10
3秒前
lx的应助被h11采纳,获得10
3秒前
3秒前
恶恶么v完成签到,获得积分10
4秒前
4秒前
4秒前
rdh完成签到,获得积分10
4秒前
兴奋的台灯完成签到 ,获得积分10
4秒前
法就发布了新的文献求助10
4秒前
shengji发布了新的文献求助10
4秒前
shangguang的应助被zzl采纳,获得10
5秒前
5秒前
6秒前
freak发布了新的文献求助10
6秒前
桃子汽水完成签到 ,获得积分10
7秒前
英俊的铭的应助被小王采纳,获得10
7秒前
夏安发布了新的文献求助10
7秒前
若梦发布了新的文献求助10
8秒前
CDD完成签到,获得积分10
8秒前
虚拟的信封完成签到,获得积分10
8秒前
8秒前
红霉素软膏完成签到,获得积分10
8秒前
贤君发布了新的文献求助20
9秒前
9秒前
隐世求开完成签到,获得积分10
9秒前
9秒前
乔治发布了新的文献求助10
9秒前
9秒前
10秒前
MM的应助被之星君采纳,获得10
10秒前
小阮完成签到,获得积分10
10秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164445
求助须知:如何正确求助?哪些是违规求助? 9558283
关于积分的说明 21744871
捐赠科研通 7754979
什么是DOI,文献DOI怎么找? 3428582
关于科研通互助平台的介绍 2553119
邀请新用户注册赠送积分活动 2473142